Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HER+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant
Target Specialties: Oncology

Ryan Rader

University of Kansas Cancer Center
Clinical Assistant Professor

Ryan Rader, MD, FACP is a clinical assistant professor of medicine at the University of Kansas School of Medicine.

Dr. Rader received his medical degree from the University of Missouri School of Medicine in Columbia, MO. He completed his internal medicine residency at the Cleveland Clinic and Hematology/Oncology fellowship at Duke University. He is board certified in Internal Medicine, Hematology, and Medical Oncology and has a special interest in breast cancer.

Dr. Rader practices at the University of Kansas Cancer Center in Lee’s Summit and is on staff at several community hospitals.